---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000006"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:27:12.381475+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma FY2025 cash $80.9M; Phase 3 sarcoidosis study misses primary endpoint

## Summary
- Phase 3 EFZO-FIT missed primary endpoint (corticosteroid dose reduction at week 48), but showed benefit in KSQ-Lung (p=0.0479) and other secondary measures.
- Type C FDA meeting scheduled mid-April 2026 to review EFZO-FIT results and determine path forward for efzofitimod in pulmonary sarcoidosis.
- Phase 2 EFZO-CONNECT in SSc-ILD on track to complete enrollment in first half 2026; interim data reported Q2 2025.
- Year-end 2025 cash position $80.9 million; R&D expenses $60.2 million, G&A $17.6 million for the year.

## SEC filing metadata
- accession: 0001339970-26-000006
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/0001339970-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/atyr-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000006
- JSON: https://secwatch.observer/filing/0001339970-26-000006.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000006.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/0001339970-26-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.